Report: Hanmi’s failure to report patient death in olmutinib study broke South Korea’s medical laws
A Korean patient taking Hanmi’s cancer drug olmutinib died from a rare case of Stevens-Johnson syndrome a full 14 months before it was reported to the country’s health authorities, triggering a scramble that ultimately caused its partner Boehringer Ingelheim to abruptly withdraw from their $730 million partnership on the drug. And today Korean officials determined that Hanmi broke two medical laws related to monitoring and reporting clinical trials, according to a report from the Korean Herald.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.